Last reviewed · How we verify
NCT07251153
Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions
Phase 1 trial testing EYP651/Vonafexor low dose in Healthy Adult Male and Female Volunteers in 40 participants. Currently enrolling.
18 December 2025
Quick facts
| Lead sponsor | Enyo Pharma |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 28 October 2025 |
| Primary completion | 18 December 2025 |
| Estimated completion | 28 October 2026 |
| Sites | 1 location across France |
Drugs / interventions tested
- EYP651/Vonafexor low dose — full drug profile →
- EYP651/Vonafexor high dose — full drug profile →
- EYP651/CYP3A4 inhibitor — full drug profile →
- EYP651/Transporter substrate — full drug profile →
- EYP651/CYP2C8 and CYP2C9 substrate — full drug profile →
Conditions studied
- Healthy Adult Male and Female Volunteers — all drugs for Healthy Adult Male and Female Volunteers →
Sponsor
Enyo Pharma — full company profile →
Who can join
Adults 18 to 65, any sex, with Healthy Adult Male and Female Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to define and compare the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EYP651 at two dose levels and compare it with Vonafexor Acid PK and PD profile, the Part A. In addition, Part B of the trial will assess the Drug-Drug Interactions (DDI) potential with the high dose of EYP651.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07251153
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Adult Male and Female Volunteers
Currently open trials in the same condition.
- NCT07413666 — A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years · Phase 1 · recruiting
- NCT07201584 — A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fas · Phase 1 · recruiting
- NCT06935682 — Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects · Phase 1 · recruiting
Other Enyo Pharma trials
Trials by the same sponsor.
- NCT06939816 — Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) · Phase 2 · recruiting
- NCT06425055 — Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) · Phase 2 · completed
- NCT04365933 — A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatit · Phase 2 · completed
- NCT04465916 — Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD) · Phase 2 · terminated
- NCT04037618 — Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07251153 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Enyo Pharma
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07251153.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing